Developing innovative drug products for the prevention and treatment of mucosal inflammatory diseases 

About True Node

In True Node  we’re committed on the development of products for indications in the mucosal inflammatory diseases space currently targeting 3 main indications:

Through creativity and strong science, we’re driving innovation that has the potential to become the next generation of safe, highly efficacious and cost effective drug products.

Our flagship technology consist in a synergistic pharmaceutical formulation of reprofiled therapeutic molecules that together intervene in different points of the mucosal inflammatory disease, reducing both the biomass (bactericidal effect) and the control of pro-inflammatory mediators, stimulating the resolution of chronic inflammation and causing a reversion of the disease.


Felipe Galvan


Felipe has an undergraduate degree in Chemical Engineering a postgraduate degree in Business Administration and a MSc in Biochemistry at the Universidad de Chile. He also studied at the University of Karlsruhe-TH in Germany, carrying out research for international companies such as P&G.

In his more than 15-year career, he has managed to stand out, leading multidisciplinary teams in various fields of research, health and industry. With technical and business skills, True Node Sciences continues to position itself in the field of bio-business.

David Rosenberg

Founder and CMO

David is Dental Surgeon from the Universidad de Chile, he pursued a MSc in Periodontology and Osseointegration at the Catholic University of Leuven (KUL Leuven, Belgium) and PhD at the International University of Catalunya, researching topics in the areas of Periodontology and Oral Medicine.

Between 2009 and 2019, David serves as the Director of Graduate Studies of the Faculty of Dentistry and part of the academic staff of Department of Oral and Maxillofacial Surgery at the Los Andes University, Chile. Dr. Rosenberg is an established lecturer and well-published researcher in International journals. He is an active member of the European Association of Osseointegration and the Academy of Osseointegration. He is currently leading the oral clinical development area at True Node.


Tomas Galvan

Founder and Director

  • Dental Surgeon from the Universidad de Chile and former professor of Chemistry at the Faculty of Dentistry at the University of Chile.
  • 40 years of experience, he has developed many initiatives in the public and private sectors. Scientist and serial entrepreneur,
  • Responsible for the development pipeline at Ingalfarma SpA an oral pharmaceutical Company based in Santiago de Chile.
  • Inventor and author of a large number of international patents.
Pablo Valenzuela

Director - Scientific Advisor

  • Ph.D. in Chemistry at Northwestern University, Post Doctor at University of California San Francisco and held a position as Professor in the Biochemistry Department of that institution.
  • In 1981 he founded Chiron Corporation, which a decade later was the second-largest biotechnology company in the world.
  • Valenzuela was responsible for the development of biotech products with a market value of nearly 8 billion dollars.
  • Inventor in more than 50 patents in Chile and abroad, in 1997 he cofounded Fundación Ciencia & Vida.
  • Recently he received the Life Time Achievement Award from the BayBio Association of California.
Rajesh Lalla

Medical Advisor

  • Board-certified clinician and scholar who conducts clinical research on a variety of oral mucosal disorders.
  • Associate Dean for Research in the School of Dental Medicine at University of Connecticut.
  • Past Chair of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (MASCC/ISOO) and a member of the MASCC Board of Directors.
  • Dr. Lalla has written more than 75 peer-reviewed scientific articles or book chapters, many of them dealing with oral complications in cancer patients.






Periodontitis affects more than 11.2% of the population and current treatments are largely ineffective. The long-term effects of this disease lead to huge healthcare costs.




Oral Mucositis is a common, severe, and debilitating side-effect of cancer treatments for patients with certain types of cancer including head and neck, for which there is no standard effective treatment available to date.




Mild to moderate Ulcerative colitis affects about 1.0 million people in the US alone, and current treatments, mainly steroids, often produce negative side effects, leading to low adherence to treatments, poor patient outcomes, and high costs.




Ulcerative Colitis


:Treatment of mild to moderate ulcerative colitis


: Prevention and treatment of moderate to severe periodontitis

Oral mucositis

: Prevention and treatment of oral mucositis and other oral ulcerative lesions

USA (Combination Product)
EU (Medical Device)
LATAM (Medical Device)


Media or Investor Inquiries

80 Broad Street, 5th Floor (PMB#6003) 

New York, NY 10004.

Partners or Business Development Inquiries

80 Broad Street, 5th Floor (PMB#6003)

New York, NY 10004. 

Ir arriba